Jason A. Amello
Jason A. Amello (born 1968) has over 25 years of corporate finance experience, contributing to strategic business growth and financial and operational performance. Prior to joining Saniona, he served as Senior Vice President, Chief Financial Officer and Treasurer of Akebia Therapeutics Inc. (Nasdaq:AKBA), where, over a seven-year period, he helped lead Akebia’s financing efforts, including its initial public offering, and served as a key advisor for Akebia’s merger with Keryx Biopharmaceuticals. During his tenure at Akebia, Amello built out the entire finance organization and was responsible for treasury management, financial planning and budgeting, accounting and reporting, taxation, procurement, facilities, and information technology. Prior to joining Akebia, Amello served as Executive Vice President, Chief Financial Officer and Treasurer of Ziopharm Oncology, Inc. (Nasdaq:ZIOP). Prior to that, he held multiple finance leadership positions at Genzyme Corporation, now Sanofi Genzyme, including Senior Vice President, Chief Accounting Officer, and he led the Strategic Financial Services group through which he served as a key advisor on all of Genzyme’s mergers and acquisitions and other strategic transactions. Earlier in his career, Amello spent 10 years in the business advisory and assurance practice of Deloitte. Amello holds a BS in Accounting from Boston College and is a Certified Public Accountant in the Commonwealth of Massachusetts.
In addition to his current position as Chief Financial Officer of Saniona, Amello currently serves on the Board of Directors of Acer Therapeutics, Inc. (Nasdaq:ACER) and the New England Baptist Hospital.
Amello holds 4,200 shares and 829,512 options in the option program 2020/2031.